Moderna’s COVID-19 vaccine set for Phase III trial
The company will begin a late-stage trial for its potential vaccine in July, with 30,000 individuals to receive mRNA-1273.
The company will begin a late-stage trial for its potential vaccine in July, with 30,000 individuals to receive mRNA-1273.
The company will have sunk nearly $2bn into the facility, after acquiring and planning to double its capacity.